Clinical Trial Update: KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating regimens of KALETRA or LEXIVA boosted with Ritonavir plus Epivir and Abacavir in HIV-naive subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Epivir (Lamivudine)
• Kaletra (lopinavir)
• Lexiva (Fosamprenavir)
• abacavir (abacavir)

Snippet

Sponsor: GlaxoSmithKline | Conditions: HIV Infection, Infection, Human Immunodeficiency Virus | Phase 3 | Status: COMPLETED